Company ProfilePremium

BLS Pharmaceuticals Limited (formerly Bioxyne Limited)

Company Profile Analysis

Ticker: BLS.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
BLS Pharmaceuticals Limited - Company showcase

Year Founded & Workforce

2018

16 Employees

BLS Pharmaceuticals Limited logo

BLS Pharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

BLS Pharmaceuticals Limited Overview

MetricFY2024FY2025FY2026
Employees (headcount)———
Employee benefits and labour hire expense (A$ M)—5.1311.30
Superannuation contributions (A$ M)—0.390.78

Source: FY2026 Annual Report (restated FY2025 comparatives). Headcount not disclosed; superannuation expense doubling is a reasonable proxy for roughly doubled Australian payroll.

BLS Pharmaceuticals is an Australian-headquartered, GMP-licensed downstream pharmaceutical manufacturer and wholesaler specialising in controlled and "special access" medicines—principally medicinal cannabis, with an emerging position in MDMA and psilocybin finished-dose products. Its core asset is a multi-jurisdictional licence stack (TGA, Office of Drug Control, Queensland Health) and a Brisbane manufacturing platform the company estimates can support over A$250m of annual revenue. Rather than cultivating or prescribing, BLS converts third-party active pharmaceutical ingredients into compliant finished doses (flower, pastilles, oils, vapes, capsules) for brand owners, clinics and distributors, and sells its own Dr Watson® brand. Revenue rose from A$5.2m in FY2023 to A$74.2m in FY2026 with A$15.4m NPAT, and FY2027 guidance is A$105–115m. Expansion levers include a A$50m German supply contract with ADREXpharma, a Scottish GMP facility, Latin American exports, and partnerships with Aurora Cannabis and Curaleaf International. Key risks are regulatory dependence, customer concentration and working-capital intensity.


Company's own description (FY2026 Annual Report)

The FY2026 Directors' Report describes BLS Pharmaceuticals as an international Australian life sciences company headquartered in Sydney and the parent of the Breathe Life Sciences group, whose subsidiaries are licensed to manufacture, import, export and supply controlled drugs and prescription medicines including cannabis, MDMA and psilocybin, supported by a multi-national licence stack. In Australia, subsidiary BLS Wholesalers Pty Ltd is described as the market-leading manufacturer of medicinal cannabis, MDMA and psilocybin products, licensed by the TGA, ODC and Queensland Health. In the UK, the subsidiary is transitioning into manufacture and supply via third-party licences until its own facility is licensed. In Germany, supply flows through local partner ADREXpharma, which holds the requisite local licences. Across all markets, the stated strategy is to replicate the Australian model, building brand equity under the Breathe Life Sciences (B2B) and Dr Watson® (patient/consumer-facing) brands.

The CEO's report articulates the vision as becoming the global leader in breakthrough and investigational medicines containing cannabis, MDMA, psilocybin and other APIs, and the strategy as becoming the market-leading manufacturer and wholesale supplier in each market served.

Business model

Revenue streamDescriptionRecognition (FY2026 accounting policy)
Sale of goods (own brands)Dr Watson® medicinal cannabis and OTC products; BLS-branded medicinesPoint in time (QA release + transfer of risks/rewards)
Contract / white-label manufacturingFinished-dose manufacture for brand owners (e.g., NectarTek, Aurora Cannabis, Curaleaf QMID cartridges)Point in time; bill-and-hold permitted under strict criteria
Pharmaceutical procurement / API sourcingSourcing raw materials and APIs from suppliers on five continentsBundled within goods sales
Storage and distributionControlled-drug storage, warehousing, wholesale distributionOver time (output method)
Import/export and market accessARTG export registrations (24 products registered FY2026), export to UK, Germany, Costa RicaBundled within goods sales
Probiotic licensing/wholesale (legacy)Lactobacillus fermentum PCC® wholesale via Chr. Hansen and Nu SkinPoint in time; A$554,868 revenue in FY2026

The Operations Report describes five connected capabilities: Sourcing/Procurement → Manufacture → Compliance & Regulatory → Import/Export → Distribute. BLS explicitly positions itself as a downstream manufacturer and distributor, avoiding the capital and agricultural risk of cultivation and not owning prescribing channels. Revenue streams include:

Payment terms: customers typically pay a deposit (generally 50%) prior to completion, with the balance on shipment; larger customers are on 30-day terms (FY2026 Annual Report, Note 1(D)). Contract liabilities (customer deposits) were A$2.66m at 30 June 2026.

Revenue model mix: predominantly product/contract manufacturing revenue (point-in-time); a small storage and distribution service component recognised over time; negligible royalty income (other income A$68k in FY2026). There is no subscription revenue. The precise split between own-brand and contract manufacturing revenue is not publicly disclosed.

Value chain position

BLS sits in the mid-to-downstream segment of the regulated medicines value chain: between API producers/cultivators (e.g., Aurora Cannabis, Cayman Chemical for psychedelic APIs) and prescribers, clinics, pharmacies and distributors (e.g., NectarTek clinics, ADREXpharma). Its moat is regulatory: few Australian companies hold the combination of GMP, controlled-drug manufacturing, import/export and wholesale licences across cannabis, MDMA and psilocybin.

Customer types and end-markets

Customer typeExamples (disclosed)End-market
Medicinal cannabis brand owners / clinicsNectarTek (exclusive manufacturer agreement)Australian prescribed medicinal cannabis (SAS-B, Authorised Prescriber)
International cultivators/manufacturersAurora Cannabis (Nasdaq/TSX-listed), Curaleaf InternationalAustralia, UK, Germany
International distributorsADREXpharma (Germany), Remidose LATAM SRL (Costa Rica, Panama)German pharmacy channel; Central American regulated cannabis
Authorised prescribers / psychedelic therapy providersUnnamed Australian clinics; clinical trials for treatment-resistant PTSDAustralian psychedelic-assisted therapy (MDMA for PTSD; psilocybin for TRD)
Consumer / OTC retailHarrods pharmacy (London), Ideal World TV shopping (UK), Amazon (UK, historically US/Japan)OTC supplements
Nutraceutical partnersChr. Hansen (Denmark), Nu Skin Enterprises (USA)Probiotic supplements (PCC®)

Independent characterisation

BLS is best understood as a licensed contract development and manufacturing organisation (CDMO) plus wholesaler for scheduled medicines, with a growing own-brand overlay. Its economics resemble a specialty CDMO: high operating leverage on a largely fixed leasehold facility, meaningful raw-material pass-through (raw materials consumed were ~49.5% of FY2026 revenue), and working-capital intensity driven by inventory held for continuity of supply. The FY2026 result (26% adjusted EBITDA margin) demonstrates operating leverage, but the revenue base remains heavily concentrated in Australian medicinal cannabis, a market exposed to regulatory and pricing changes. The psychedelic franchise is strategically important but commercially immaterial today (e.g., initial psilocybin sales of 250 doses, sufficient for ~60 patients).

Strategy

Stated strategy themes (FY2026 Annual Report)

Vision: "Redefining medicine for a healthier tomorrow" — to be the global leader in breakthrough and investigational medicines containing cannabis, MDMA, psilocybin and other APIs.

Four strategic priorities (Operations Report):

  1. Scale the established Australian platform — lift Brisbane utilisation (capacity >A$250m revenue p.a.) via additional shifts without proportionate capex; grow existing customers; broaden dose forms.

  2. Build an integrated international GMP footprint — Australia as principal base; Scotland for UK/EU supply; convert German relationships into recurring supply; partner with local importers elsewhere rather than replicating infrastructure.

  3. Become a preferred downstream pharmaceutical partner — offer GMP finished-dose manufacture, controlled-drug handling, import/export, wholesale and regulatory support to API holders lacking licences (Aurora cited as proof point).

  4. Broaden product categories — MDMA, psilocybin, Dr Watson portfolio near term; ibogaine, peptides, ibuprofen and other approved medicines under evaluation; longer-term proprietary formulations, combination medicines, delivery formats and process IP.

Overarching principle: disciplined growth—increase utilisation of existing platform before committing material capital; selective, accretive partnerships or acquisitions only.

Initiatives announced in the last 24 months

InitiativeDateDescriptionStatus
Australian in-house manufacturingAug 2024Start of BLS-owned GMP manufacturingComplete; scaling
Capacity expansionH1 FY2026Clean rooms +100%; storage +200%; pastille capacity up to 6m/monthComplete
German market entryJun 2025 → May 2026€3.2m Adrex agreement expanded to ~A$50m two-year exclusive Dr Watson distributionExecuting
Frankfurt dual listingOct 2025PR8.F for European capital accessComplete
Scotland GMP facilityOct 2025–Dec 2026SOSE-backed (£500k loan; grants up to ~£348k—£848,250 total SOSE package) facility; capex A$2.1m to 30 June 2026Construction/commissioning
LATAM entryDec 2025 → May 2026Remidose Costa Rica/PanamaFirst sales FY2026
Curaleaf QMIDNov 2025Exclusive device + cartridge supplyLaunched
Aurora Cannabis manufacturingApr 2026Oils and vapes for AU, expanding to UK and DECommenced
Cayman Chemical referralJul 2026Psychedelic API customer referralsSigned
Trexapharm explorationFY2026Nasal spray and injectable formatsExploratory
PTSD combination medicine / drug development pipelineFY2026Accelerate clinical evidence for BLS-owned MDMA and psilocybin medicines (PTSD, TRD)Early stage
US export ambitionFY2026Work toward export of MDMA/psilocybin capsules to the US following breakthrough-therapy designationsAspirational; no US presence
Corporate rebrand and consolidationJun–Jul 2026Name change to BLS Pharmaceuticals; 1:10 consolidationComplete
Westpac overdraftPost 30 Jun 2026A$3m undrawn facilityComplete

ESG/sustainability commitments and formal cost programmes: none publicly disclosed.

Guidance and medium-term targets

MetricFY2025 actualFY2026 initial guidanceFY2026 upgraded guidanceFY2026 actualFY2027 guidance
Revenue (A$ M)28.465–7565–7574.2105–115
Adjusted EBITDA (A$ M)7.011.5–13.516.5–19.019.0~24–30 implied
Adjusted EBITDA margin (%)25——2623–26

FY2027 implied adjusted EBITDA (A$24.2–29.9m) is derived by applying the margin range to the revenue range. Longer-term capacity statements: c.A$250m p.a. Australian revenue capacity plus c.A$150m from the UK facility (company estimates, not targets).

Products & Services

Medicinal cannabis (principal commercial category)

Product / platformDescriptionTarget customerLaunch / statusPricing
Dr Watson® medicinal cannabis flowerOwn-brand GMP dried flower; three flower products exported to Costa Rica via RemidosePatients via prescribers/pharmacies (AU); distributors (DE, LATAM)Australian sales ongoing; Costa Rica first sale >A$0.5m (FY2026)—
Dr Watson® medicinal cannabis (Germany)Exclusive distribution by ADREXpharma under two-year ~A$50m agreementGerman pharmacy networkAgreement May 2026—
THC pastillesPharmaceutical-grade THC pastilles; company describes the world's largest GMP-certified cannabis pastille facility (capacity up to 6 million pastilles/month)Brand owners; Remidose (LATAM)Scaled during FY2026—
Oils (sublingual)Cannabis oils manufactured for own and third-party brands; Aurora initial scope >5,000 unitsAurora Cannabis; Australian patientsFY2026—
Vape / inhalable productsCannabis liquid inhalants; Aurora initial sales >20,000 vape units; expansion to UK and GermanyAurora Cannabis; prescribersFY2026—
Que Medical Inhalation Device (QMID)Exclusive Australian import, manufacture (including API and cartridge filling) and supply for Curaleaf International; recurring device + cartridge modelAuthorised prescribers, SAS-B, pharmaciesTGA import approval 1 Oct 2025; ODC authorisation 27 Oct 2025; launch Nov 2025—
White-label / contract manufacturingFinished-dose manufacture for third-party brands (e.g., NectarTek exclusive for AU, UK, DE)Clinics, brand ownersNectarTek agreement April 2025 (≥A$7m FY2026 committed)Contract-specific
ARTG-registered export products24 cannabis-based medicinal products registered on ARTG for export in FY2026Export markets (UK, DE, LATAM)FY2026Not applicable

Psychedelic medicines

ProductDescriptionTargetStatus
BLSMD40 / BLSMD100 (MDMA capsules)GMP-manufactured MDMA capsules (40mg / 100mg nominal from product codes); first Australian-made GMP-certified MDMA capsulesAuthorised Prescribers (PTSD); clinical trials in treatment-resistant PTSDCommercial batch production from July 2025; first commercial supply H1 FY2026; 400+ patient doses supplied (per Dr. Reuter Investor Relations, Feb 2026)
BLSPSIL25 (psilocybin capsules)GMP psilocybin capsules (25mg nominal from product code)Authorised Prescribers (treatment-resistant depression)Initial sale of 250 doses (~60 patients over 12 months) in FY2026
Combination medicine for PTSDProprietary combination medicine under developmentPTSD patientsAnnounced FY2026; pre-commercial
Psychedelic API access (Cayman Chemical referral)Cayman Chemical refers psilocybin/MDMA API customers to BLS for patient-ready dosage manufactureGlobalAgreement 21 Jul 2026

New dose forms and pipeline categories

InitiativeDescriptionStatus
Trexapharm exploratory agreementNasal spray and injectable dose formsExploratory (FY2026)
Ibogaine, peptides, ibuprofenEvaluated as potential new regulated product categoriesEvaluation; company states these are not committed programs
Novel delivery mechanisms / proprietary formulationsIP development in dose forms and delivery for MDMA and psilocybinEarly stage

Consumer health / OTC

ProductDescriptionChannelStatus
Dr Watson® OTC supplementsOver-the-counter supplement rangeHarrods pharmacy (London); Ideal World (UK TV shopping, channel 51); AmazonActive (launch dates not disclosed)
Lactobacillus fermentum PCC®Proprietary probiotic strain for gut health/immune supplementsChr. Hansen (global distribution); Nu Skin (USA)Legacy; A$0.55m FY2026 revenue
Progastrim (nano-encapsulated)Probiotic product update with improved shelf life (planned 2H 2023 launch)BLS e-commerceCurrent status not disclosed
BLS ClinicsOnline telehealth service launched June 2023PatientsCurrent status not disclosed
Mirai Solution / CanXChangeJapan consumer health brand / platform referenced in Morningstar profileJapanCurrent status not disclosed

Services

ServiceDescription
Pharmaceutical input sourcing / procurementGlobal API and raw material sourcing (suppliers on five continents)
Product developmentFormulation and dose-form development for clients
Packaging and QA releaseGMP quality assurance
Controlled-drug storageStorage capacity increased 200% in H1 FY2026
Import / exportODC permits; ARTG export registrations
Wholesale distribution and market accessSupply to pharmacies, prescribers and distributors

Financial Narrative

Basis: FY2022 reflects Breathe Life Sciences standalone (reverse-acquisition accounting acquirer); FY2023 includes legacy Bioxyne only from 19 May 2023. FY2025 figures are the restated comparatives in the FY2026 Annual Report.

Income statement

Sources and derivations: FY2023 revenue A$5,160,538 and FY2022 A$463,636 (FY2023 Appendix 4E); FY2024 revenue A$9,655,752 and loss A$13,325,050 (FY2025 Appendix 4E); FY2022–FY2024 gross profit, EBIT and PBT per Stockopedia (FY2024 revenue there is A$9.33m—discrepancy vs. A$9.66m in the Appendix 4E). FY2024 EPS of (0.67) cents pre-consolidation restated ×10. FY2025–FY2026 per FY2026 Annual Report. Materials margin = revenue − raw materials consumed + change in inventories (company does not report gross profit under by-nature presentation). Statutory EBITDA = PBT + finance costs + D&A; adjusted EBITDA further adds back share-based payments (A$1.97m FY2026; A$1.21m FY2025), reconciling to the company's reported A$19.0m and A$7.0m. FY2024 loss includes an A$11.57m goodwill write-down; underlying FY2024 operating loss was A$1.41m (FY2025 Appendix 4E).

Margins

Note: FY2022–FY2024 gross margins use aggregator gross profit (cost-of-sales basis) and are not comparable with FY2025–FY2026 materials margins (by-nature basis, excluding labour).

Revenue CAGR: FY2022–FY2026 ≈ 256% (4-year; distorted by reverse-acquisition base); FY2023–FY2026 ≈ 143% (3-year); FY2024–FY2026 ≈ 177% (2-year).

FY2026 expense structure (by nature)

Commentary: Operating leverage is visible in fixed-cost lines—employee costs grew 120% against revenue growth of 161%, and "other expenses" rose only 9%. Variable costs (raw materials, commission, freight) grew broadly in line with or faster than revenue, compressing the materials margin by ~4 percentage points, consistent with a mix shift toward contract manufacturing and international supply (ADREX pricing) relative to higher-margin own-brand domestic sales. Marketing expense more than quadrupled as international brand activity (Dr Watson in Germany/UK) ramped. FY2026 benefited from an A$0.24m tax benefit (recognition of deferred tax assets on Australian losses), so pre-tax earnings are the better quality measure; the Australian tax group moved from a 25% base-rate entity to the 30% full rate, and with unrecognised Australian losses now largely used (A$4.0m remaining unrecognised overseas-related losses vs. A$23.8m a year earlier), a normalised tax charge should emerge in FY2027.

Half-year progression

Sources: H1 FY2025 and H1 FY2026 per company results releases; H2 figures derived as full year less H1. The H1 FY2026 presentation charts H1 FY2025 adjusted EBITDA as A$3.5m and H2 FY2025 as A$1.9m on a different basis—a discrepancy versus the A$3.7m originally reported and versus the restated FY2025 full-year A$7.0m.

Balance sheet

Source: FY2026 Annual Report, Consolidated Statement of Financial Position. Negative net debt denotes net cash.

Commentary: The balance sheet nearly tripled in FY2026. The dominant movement was inventory (+A$14.2m to A$17.8m), which the Board attributes to stock held against forecast demand, continuity-of-supply obligations and larger international programmes (notably ADREX). Right-of-use assets rose ~A$3.9m, consistent with expanded Brisbane premises (lease to February 2029 with a five-year option recognised). Debt remains modest: a 9.5% bank loan secured over Meadowbrook premises fit-out, 8–9% equipment finance, the £500k SOSE loan (9.5%, 60 months, nine-month capital holiday), and a product loan forgiven if product is unsold. Intangibles are negligible following the FY2024 goodwill write-off, so book equity is almost entirely tangible. Accumulated losses of A$10.7m flipped to retained earnings of A$4.4m.

Cash flow

Source: FY2026 Annual Report. FY2026 capex is gross of A$0.45–0.5m SOSE grant receipts netted in investing flows. Lease principal repayments sit in financing and are not deducted from the FCF measure above.

Commentary: Cash conversion weakened sharply—OCF fell to 28% of adjusted EBITDA (FY2025: ~90%) as working capital absorbed ~A$13m. The June 2026 quarter was a turning point, generating record OCF of ~A$6.3m, implying the first nine months of FY2026 consumed ~A$0.9m of operating cash. Management states supplier terms are being improved and expects better cash generation in FY2027. Equity funding in FY2026 was minor (option conversions A$1.34m; placement A$0.11m), so growth has been largely self-funded.

Ratios

Derivations by analyst from FY2026 Annual Report data. ROIC uses EBIT × (1 − 25% FY2025 / 30% FY2026) over equity + debt incl. leases − cash. Working-capital days use materials cost (raw materials less inventory change) as the COGS proxy; payables include non-trade items, so DPO is overstated. These ratios are indicative only.

Commentary: Returns are exceptionally high for a manufacturer because the asset base is light (leased facility, small PP&E) and equity was depressed by historical losses. The deterioration in the cash conversion cycle from roughly neutral to ~129 days is the single most important financial trend to monitor: inventory days almost doubled while payables days shortened. Receivables quality also softened modestly—the expected-credit-loss allowance rose to A$0.37m, with A$0.41m of receivables more than two months overdue (60% provisioned).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryFunction (as disclosed or inferred from disclosures)

BLS Pharmaceuticals Limited

Australia

Listed parent, head of tax-consolidated group

Breathe Life Sciences Pty Ltd

Australia

Operating group holding / brand owner

BLS Wholesalers Pty Ltd

Australia

Licensed (TGA, ODC, QLD Health) manufacturer and wholesaler

BLS Panther Pty Ltd

Australia

—

Breathe Life Science UK Ltd

United Kingdom

UK operations; Scottish facility; borrower under SOSE loan

Always Pure Organics EU

Czech Republic

European operations (Czechia expansion plans on hold)

Mirai Solution Co KK

Japan

Japanese consumer health operations

Dr Watson Japan KK

Japan

Dr Watson brand, Japan

Global Treasure New Zealand Ltd; New Zealand Nutritional Research Institute Ltd; Bioxyne International (NZ) Ltd

New Zealand

Legacy entities (non-controlling interest acquired FY2026)

Bioxyne International Malaysia Sdn Bhd; P.T. Gamata Utama

Malaysia; Indonesia

Discontinued SE Asia direct selling; being deregistered

Bioxyne International Pty Ltd

Australia

Legacy direct-selling entity

“—” = not publicly disclosed.

Revenue by Segment

Segment (as reconstructable)FY2024FY2025FY2026

Total revenue from customers (AUD Mn)

9.6628.4374.16

PCC probiotic wholesale revenue (AUD Mn)

——0.55

Pharmaceutical manufacturing and distribution, derived (AUD Mn)

——73.61

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (Quarterly)

MetricQ1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026

Revenue (AUD Mn)

14.017.321.421.7

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from customers (AUD Mn)

0.465.169.6628.4374.16

Revenue growth (%)

—1,01387194161

Gross profit per aggregator (AUD Mn)

0.141.903.40——

Materials margin, derived (AUD Mn)

———17.1041.56

Operating income / EBIT (AUD Mn)

-0.50-2.15-13.305.0315.62

Statutory EBITDA (AUD Mn)

———5.8117.00

Adjusted EBITDA, company definition (AUD Mn)

———7.0118.97

Profit before tax (AUD Mn)

-0.49-1.96-13.004.9015.16

Net income attributable (AUD Mn)

-0.49-1.94-13.334.9015.40

Basic EPS, post-consolidation (A$ cents)

——-6.72.46.9

Diluted EPS, post-consolidation (A$ cents)

——-6.72.36.7

Dividends per share (A$ cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross / materials margin (%)

29.136.835.260.156.0

EBIT margin (%)

—-41.7-137.717.721.1

Statutory EBITDA margin (%)

———20.422.9

Adjusted EBITDA margin (%)

———24.725.6

Net margin (%)

-106.5-37.6-138.017.220.8

Expense line (AUD Mn)

Expense line (AUD Mn)FY2025FY2026

Raw materials and consumables used

12.1036.70

Change in inventories (credit)

0.774.10

Employee benefits and labour hire

5.1311.30

Commission

0.731.84

Freight and transportation

0.921.83

Marketing

0.411.84

Subscriptions and data

0.001.05

Professional and consulting fees

1.061.35

Depreciation and amortisation

0.781.39

Share-based payments

1.211.97

Impairment of receivables

0.000.25

Finance costs

0.130.46

Other expenses

2.712.95

Income Statement

MetricH1 FY2025H2 FY2025H1 FY2026H2 FY2026

Revenue (AUD Mn)

12.615.831.342.9

Adjusted EBITDA (AUD Mn)

3.73.38.310.7

NPAT (AUD Mn)

——7.38.1

Balance Sheet and Per-Share Data

MetricFY2025FY2026

Total assets (AUD Mn)

19.5852.08

Cash and equivalents (AUD Mn)

7.6713.29

Trade receivables (AUD Mn)

2.357.65

Inventories (AUD Mn)

3.6117.82

Plant and equipment (AUD Mn)

2.335.09

Right-of-use assets (AUD Mn)

1.044.97

Goodwill and intangibles (AUD Mn)

0.390.39

Borrowings, current (AUD Mn)

0.071.09

Borrowings, non-current (AUD Mn)

0.281.93

Lease liabilities, total (AUD Mn)

1.195.41

Total debt incl. leases (AUD Mn)

1.538.43

Net debt incl. leases (AUD Mn)

-6.13-4.86

Net debt excl. leases (AUD Mn)

-7.32-10.27

Trade and other payables (AUD Mn)

4.779.66

Contract liabilities (AUD Mn)

1.062.66

Total current assets (AUD Mn)

15.7441.21

Total current liabilities (AUD Mn)

6.4014.22

Working capital (AUD Mn)

9.3426.99

Total equity (AUD Mn)

12.1031.09

NTA per share, post-consolidation (A$ cents)

5.413.3

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

———6.285.41

Capex, PP&E gross (AUD Mn)

———2.103.80

Net investing cash flow (AUD Mn)

———-2.07-3.55

Free cash flow, OCF less net investing (AUD Mn)

———4.211.87

Net financing cash flow (AUD Mn)

———2.423.76

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Cash receipts from customers (AUD Mn)

————76.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE, closing equity (%)

40.549.5

ROE, average equity (%)

—71.3

ROA, closing assets (%)

25.029.6

ROIC, notional NOPAT / invested capital (%)

63.241.7

Current ratio (x)

2.462.90

Quick ratio, per Eulerpool (x)

1.181.90

Debt / equity incl. leases (x)

0.130.27

Net debt / adjusted EBITDA (x)

-0.87-0.26

Interest coverage, EBIT / finance costs (x)

39.333.9

Asset turnover, closing assets (x)

1.451.42

Days sales outstanding (days)

3038

Days inventory outstanding, on materials cost (days)

116199

Days payables outstanding, on materials cost (days)

154108

Cash conversion cycle (days)

-8129

Revenue by Region

RegionFY2024FY2025FY2026

Total group revenue (AUD Mn)

9.6628.4374.16

Germany, ADREX shipments H1 only (AUD Mn)

——2.7

Costa Rica, initial commercial sale (AUD Mn)

——0.5

PCC probiotic wholesale, global (AUD Mn)

——0.55

Share Price & Returns

PeriodReturn (%)Start price (AUD)

1 month

-11.70.94

3 months

38.30.60

Year to date (from 31 Dec 2025)

97.60.42

1 year

80.40.46

3 years

361.10.18

5 years

196.40.28

Since inception (Apr 2012 data start)

-39.11.33

Share Price

MetricFY2025FY2026

Approx. year-end share price, post-consolidation (AUD)

0.460.94

Valuation Snapshot

MultipleValueBasis

Market capitalisation

A$202m

229.98m shares

Enterprise value

A$197m

Market cap − cash A$13.3m + borrowings A$3.0m + leases A$5.4m

Trailing P/E

13.1x

FY2026 NPAT A$15.4m (includes A$0.24m tax benefit)

Trailing P/E, tax-normalised at 30%

19.1x

PBT A$15.16m × 0.7

EV / adjusted EBITDA (trailing)

10.4x

A$19.0m

EV / adjusted EBITDA (FY2027 guidance midpoint)

7.3x

A$110m × 24.5% ≈ A$27m

EV / sales (trailing)

2.7x

A$74.2m

EV / sales (FY2027 midpoint)

1.8x

A$110m

P / book

6.5x

Net assets A$31.1m

Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (A$ cents)

00000

Shares on issue at year end, post-consolidation basis (M)

————229.98

Capital Markets

ItemDetail

Credit ratings (Moody's/S&P/Fitch)

None — unrated

Bank loan

~A$0.7m, 9.5%, 60-month term, secured over Meadowbrook fit-out

SOSE project loan

£500k (≈A$1.0m), 9.5%, 60 months from Dec 2025, 9-month capital holiday

Equipment finance and product loan

~A$1.3m combined, 8–9% (product loan forgiven if product unsold)

Lease liabilities

A$5.4m (Brisbane lease to Feb 2029 plus 5-year option)

Overdraft

A$3.0m Westpac, undrawn (post year end)

Maturity profile (AUD Mn)

Current (FY2027)

Borrowings

1.09

Lease liabilities

0.56

Analyst Conclusions

Management guidance

FY2027 revenue of A$105–115m (+42% to +55%) and adjusted EBITDA margin of 23–26% (implied A$24–30m adjusted EBITDA), underpinned by continued Australian demand on spare capacity, execution of the ADREX contract, completion of the Scottish facility (by end 2026), and a favourable regulatory backdrop for cannabis, MDMA and psilocybin medicines. The Board also expects improved cash generation through better supplier terms. No consensus exists to compare against.

Bull case

  1. Embedded growth is largely contracted or capacity-backed. The ADREX minimum (A$25m in the first 12 months) plus a full year of Aurora and Curaleaf QMID supply covers a large part of the A$31–41m revenue uplift implied by guidance, while Brisbane runs at roughly 30% of estimated revenue capacity.

  2. Valuation is undemanding if guidance is met. At ~7x FY2027 EV/EBITDA midpoint for a business compounding revenue above 40% with 20%+ ROE and net cash, a re-rating toward specialty-pharma CDMO multiples is plausible as the rebrand, Frankfurt listing and consolidation broaden the investor base.

  3. Psychedelic and international optionality is underpriced. BLS is an early GMP supplier of MDMA and psilocybin with a Cayman Chemical channel and a UK facility (c.A$150m capacity) coming online, giving exposure to strategic interest evidenced by large pharma transactions in psychedelics.

Bear case

  1. Earnings quality and cash conversion. OCF covered only 28% of adjusted EBITDA; inventory quintupled to A$17.8m; reporting has required several restatements, a revised 4C and an auditor change. If inventory does not convert, FY2027 could require external funding.

  2. Concentration and regulatory fragility. Revenue depends on Australian prescribing pathways and a small number of contracts (NectarTek terminable on six months' notice; ADREX a single German channel). A TGA policy shift or loss of one partner could erase a large share of growth.

  3. Margin pressure and tax normalisation. Materials margin fell four points as mix shifted to contract and export supply; guidance already allows margins to slip to 23%; and a full 30% tax charge means EPS growth will lag EBITDA growth in FY2027.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Late Oct 2026Q1 FY2027 4C: revenue run-rate vs. A$26–29m/quarter needed for guidance; inventory drawdown; OCF
Nov 2026AGM: remuneration vote (first-strike risk), Board renewal
Q4 CY2026Scotland facility completion and UK Home Office/MHRA licensing (~Dec 2026)
OngoingADREX order flow against A$25m year-one minimum
Feb 2027H1 FY2027 results; guidance reaffirmation/upgrade
26 Mar 2027Expiry of A$0.50 options (4.25m) — potential A$2.1m inflow
OngoingTGA/Australian regulatory developments on medicinal cannabis prescribing and driving laws
OngoingAny acquisition announcement (Board assessing opportunities)
OngoingNew international partners (UK, EU, LATAM, potential US export pathway for psychedelics)
OngoingSell-side coverage initiation post rebrand

Analyst verdict

BLS Pharmaceuticals has completed one of the more striking transformations on the ASX small-cap board: from a sub-A$1m-revenue probiotic and direct-selling shell to a profitable, A$74m-revenue licensed manufacturer of controlled medicines in three years. The core thesis is sound and evidenced. Its licence stack across cannabis, MDMA and psilocybin is genuinely scarce, its downstream, asset-light model has produced a 26% adjusted EBITDA margin on modest capital, and management has repeatedly met or beaten guidance. FY2027 guidance of A$105–115m appears credible given contracted German volumes and substantial spare Brisbane capacity, and the stock's implied forward multiple (~7x EV/EBITDA at around A$0.88) does not demand heroic assumptions.

The investment case, however, is now less about growth than about quality. FY2026 exposed three weaknesses that a larger institutional audience will scrutinise: poor cash conversion driven by a five-fold inventory build; a run of reporting inconsistencies (multiple FY2025 revenue figures, restated presentation, a revised cash-flow report, a gap between unaudited and audited revenue, and a mid-year auditor change); and a governance structure—half-independent board, no standing committees, founder holding about a quarter of shares—that is light for a company approaching a A$200m valuation and operating in heavily regulated markets. Disclosure on customer concentration, geography and segment profitability is also thin relative to the risks.

On balance, BLS screens as an attractive but higher-risk compounder: the operating platform and contracts justify a constructive view, while the balance of evidence argues for position sizing that respects regulatory concentration and execution risk. The decisive datapoints over the next two quarters are inventory conversion into cash, ADREX order delivery against minimums, and licensing of the Scottish facility. Delivery on all three, alongside committee formation and fuller segment disclosure, would materially de-risk the story and support a re-rating; slippage on cash conversion would quickly shift the narrative toward funding risk.


It is not financial advice. Figures marked as derived are analyst calculations from company filings; aggregator data is flagged where used and may contain errors. Verify current share price and any announcements after 31 August 2026 before relying on this analysis.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducation

Anthony (Tony) Ho

Non-Executive Independent Chairman

30 Oct 2012

Former executive director of Arthur Yates & Co (retired 2002); CFO/finance director roles at M.S. McLeod Holdings, Galore Group, Edward H O'Brien group; former partner of Cox Johnston & Co (now EY). Chairman of NZX/ASX-listed Truscreen Group; former chairman of Cannasouth, Energy Transition Minerals, Credit Intelligence; former NED of Hastings Technology Metals

B.Com (UNSW); Grad Dip Marketing (UTS); CA; FAICD; FCG(CS); FGIA

Samuel (Sam) Watson

Managing Director and CEO

19 May 2023

Founder of Breathe Life Sciences and Dr Watson brand (2018); CEO and founder of Breathe International Ltd (largest shareholder)

BSc Finance and Economics (NYU Stern)

Jason Hine

Executive Director and COO

19 May 2023

Former GM Commercial Operations, ECS Botanics (ASX medicinal cannabis/hemp); 30-year career including executive directorships across manufacturing, power distribution, finance, consulting

—

Edward (Ed) Myer

Non-Executive Director (described as independent in Q4 FY2026 report)

3 Jun 2026

Investor/executive via MWP Partners Ltd; capital markets experience with global investment banks in London, Hong Kong and Australia

B.Bus (Marketing, Monash); Grad Dip Applied Finance (Macquarie); GAICD

“—” = not publicly disclosed.

Executive Leadership Team

NameRoleSinceBackground

Sam Watson

CEO / MD

2023 (BLS since 2018)

See above

Jason Hine

COO

2023

See above

Guy Robertson

CFO and Company Secretary

1 Sep 2016

30+ years as director/CFO/Co Sec in Australia, NZ and Hong Kong; Jardine Matheson group roles including GM Finance Franklins Supermarkets, COO/CFO Colliers Jardine Asia Pacific, CFO and MD (NSW) Jardine Lloyd Thompson. B.Com (Hons), CA

Jason Stephens

Senior officer (among top five remunerated, non-KMP)

——

Macdarragh O'Neill

Senior officer (among top five remunerated, non-KMP)

——

“—” = not publicly disclosed.

Directors' Shareholdings

ExecutiveFixed package from 1 Jul 2025 (AUD)NoticeFY2026 performance rights granted (tranches)

Sam Watson

350,000

6 months

Share-price (>A$0.60, >A$0.80 post-consolidation), FY2026/FY2027 revenue and EBITDA targets, individual KPIs

Jason Hine

240,000

3 months

As above

Guy Robertson

141,600

1 month

As above

Governance Overview

AttributeStatus

Board size

4

Independent directors

2 of 4 (Ho; Myer) — not a majority independent board (ASX Recommendation 2.4 not met on this basis)

Chair/CEO separation

Yes; independent chair

Committees

None separately constituted; full Board performs audit & risk and remuneration & nomination functions

Board meetings FY2026

11 (full attendance by all directors in office)

Governance framework

ASX Corporate Governance Principles (4th ed.); statement approved 28 August 2026

Major Shareholders

HolderStakeSource

Breathe International Limited (controlled by Sam Watson)

26.53% (576,268,527 shares pre-consolidation ≈ 57.6m post)

Substantial holder notice per InvestSMART

Total KMP holdings (incl. Watson-controlled Breathe International and Zonetech Wellness)

72,893,447 shares at 30 June 2026 ≈ 31.7% of issued capital

FY2026 Annual Report

Directors' total holdings at report date

71,382,947 shares; 4,900,000 performance rights; 20,000 options

FY2026 Annual Report

Other substantial holders / top-20 holders

Not publicly disclosed in sources reviewed (contained in Annual Report shareholder information section)

—

Institutional ownership

Not publicly disclosed; company references a growing institutional and international shareholder base. Not held by any ETFs (InvestSMART)

—

Board & Management Changes

DateChange

19 May 2023

Sam Watson and Jason Hine join Board on BLS acquisition

29 Jan 2026

Auditor changed: RSM Australia → Pitcher Partners

3 Jun 2026

Edward Myer appointed NED

Competitive Landscape

Competitors by Segment

SegmentCompetitorType / listingRelative positioning vs. BLS

Australian medicinal cannabis manufacturing

Little Green Pharma

ASX-listed; vertically integrated cultivator/manufacturer (AU, Denmark)

Owns cultivation; BLS is asset-lighter, broader dose-form and controlled-drug scope

Australian medicinal cannabis manufacturing

Cann Group

ASX-listed; cultivator/manufacturer

Cultivation-heavy, capital intensive; BLS avoids cultivation risk

Australian medicinal cannabis

ECS Botanics

ASX-listed; Tasmanian cultivator, hemp foods

COO Jason Hine is ex-ECS; cultivation-led

Australian medicinal cannabis distribution / brands

Montu

Private; large telehealth/distribution platform

Prescribing/distribution channel—potential customer and competitor for own-brand sales

Australian medicinal cannabis distribution

Vitura Health

ASX-listed; distribution, telehealth (Canview)

Channel-focused; BLS is manufacturing-focused

Global cannabis majors in Australia

Curaleaf International; Aurora Cannabis; Tilray

Listed (TSX/Nasdaq/CSE)

Currently BLS partners/customers (Curaleaf, Aurora); could in-source or switch

Psychedelic API / finished-dose supply into Australia

Optimi Health

CSE-listed (Canada); MDMA/psilocybin GMP supplier

Direct competitor for Authorised Prescriber supply

Psychedelic API / natural psilocybin

Filament Health

Listed (Canada); natural psilocybin drug candidates

Competitor in psilocybin supply

Psychedelic drug development

Compass Pathways (psilocybin COMP360); MindMed; Gilgamesh (acquired by AbbVie)

Nasdaq / big pharma

Drug developers rather than CDMOs; potential future customers or competitors if approved products displace compounded/SAS supply

Australian psychedelic clinics

Emyria

ASX-listed; MDMA-assisted therapy clinics

Downstream; potential customer

UK cannabis-based medicinal products

UK licensed manufacturers/importers (e.g., Grow Pharma, Curaleaf UK)

Private / listed

BLS UK facility will compete for UK GMP manufacture

German medical cannabis

Demecan, Aurora Deutschland, Cantourage, Tilray Germany

Private / listed

ADREX channel competes for German pharmacy share

Competitor Detail

MetricBLS Pharmaceuticals

Latest FY revenue (AUD Mn)

74.2

Revenue growth (%)

161

Adjusted EBITDA margin (%)

26

Company Snapshot

16

Employees

2018

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Exceptional growth with profitability: Revenue grew 161% to A$74.2m in FY2026 with NPAT of A$15.4m and adjusted EBITDA of A$19.0m (26% margin) (FY2026 Annual Report).
  • Guidance credibility: FY2025 guidance upgraded twice (A$25m → A$28m) and beaten; FY2026 revenue landed at the top of A$65–75m guidance and adjusted EBITDA at the top of the upgraded A$16.5–19.0m range.
  • Licence stack moat: TGA, ODC and QLD Health licences covering cannabis, MDMA and psilocybin manufacture, import, export and wholesale; GMP certificates under MRAs with five countries; 24 ARTG export registrations.
  • Spare capacity / operating leverage: Brisbane platform estimated at >A$250m revenue capacity versus A$74m achieved; fixed "other expenses" rose only 9% on 161% revenue growth.
  • Strong, low-leverage balance sheet: Cash A$13.3m vs. borrowings A$3.0m; net assets A$31.1m; current ratio 2.9x; new A$3m undrawn Westpac overdraft.
  • Contracted international volume: ~A$50m two-year ADREX agreement with A$25m minimum in the first year; Aurora and Curaleaf partnerships.

Weaknesses

  • Cash conversion deterioration: OCF of A$5.4m was only ~28% of adjusted EBITDA; inventory rose from A$3.6m to A$17.8m (DIO ~199 days on analyst estimate).
  • Reporting quality issues: FY2025 revenue reported on four different bases (A$28.4m–A$30.4m); FY2025 P&L reclassified; performance-rights disclosures restated; unaudited FY2026 revenue (A$74.98m) exceeded audited (A$74.2m); a revised Appendix 4C was lodged in January 2026; auditor changed mid-year.
  • Governance structure: Only 2 of 4 directors independent; no separate audit or remuneration committees; 21.9% vote against the FY2025 remuneration report.
  • Concentration on Australia and cannabis: Psychedelics remain immaterial (e.g., 250 psilocybin doses sold); PCC legacy revenue only A$0.55m.
  • Thin disclosure: No segment profitability, geographic split, customer concentration or headcount disclosed in sources reviewed.
  • Key-person dependence: Founder-CEO Watson controls ~26.5% via Breathe International and drives strategy and partnerships.

Opportunities

  • Germany: ADREX minimum A$25m in the first 12 months could add a third of FY2026 revenue on its own.
  • UK manufacturing: Scottish facility with c.A$150m estimated revenue capacity and SOSE support; licensing targeted ~December 2026.
  • Psychedelics: First Australian-made GMP MDMA capsules; 400+ patient doses supplied; Cayman Chemical referral channel; US breakthrough-therapy designations open a potential export path.
  • New dose forms: QMID device + cartridges (recurring); nasal/injectable formats with Trexapharm; pastille capacity of 6m/month.
  • LATAM: First-mover position in Costa Rica and Panama via Remidose.
  • M&A optionality: Strong balance sheet, re-rated equity and Frankfurt listing support accretive bolt-ons in licences or market access, which the Board says it is assessing.

Threats

  • Regulatory change: Licences must be renewed by federal and state regulators; any tightening of Australian prescribing pathways would hit core revenue (risk factor, FY2026 Annual Report).
  • Customer/partner dependence: Loss of a key relationship (e.g., ADREX, NectarTek—terminable on six months' notice) could materially reduce revenue.
  • Inventory obsolescence: A$17.8m inventory in a market with product-specific regulatory and shelf-life constraints.
  • Price competition: Increasing licensed capacity in Australia and Europe could compress contract-manufacturing pricing; materials margin already fell from 60% to 56%.
  • Execution risk abroad: Czechia plans already paused; Scotland commissioning dependent on Home Office/MHRA licensing.
  • Tax normalisation: FY2026 NPAT benefited from a tax credit; a 30% tax rate on FY2027 profits will slow EPS growth relative to EBITDA growth.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Apr 2025Exclusive ≥A$7m NectarTek manufacturing agreementAnchors FY2026 contract volume; 200% uplift on expected FY2025 NectarTek revenue
Apr 2025A$3m placement completes; 57.8m attaching options issued (pre-consolidation)Last meaningful equity raise; options later largely exercised
12 Jun 2025FY2025 revenue guidance raised to A$28m; MDMA capsules to commercial production in JulySecond upgrade in FY2025
Jun 2025€3.2m Adrex manufacturing and supply agreement (Germany)First EU commercial entry
Jul 2025Q4 FY2025: record quarterly revenue A$9.5m (+204% YoY); positive operating cash flowExceeded FY2025 guidance
Aug 2025FY2026 guidance: revenue A$65–75m, EBITDA A$11.5–13.5mSets >2x growth expectation
29 Aug 2025FY2025 results: NPAT A$4.9m; OCF A$6.3mFirst significant profit
2H CY2025GMP certificates under MRAs with five countries; A$5.6m German API supply dealInternational regulatory recognition
9 Oct 2025SOSE funding agreement executedNon-dilutive UK capex funding
Oct 2025Frankfurt dual listing (PR8.F)European investor access
1 & 27 Oct 2025TGA import approval and ODC import authorisation for Curaleaf QMIDRegulatory clearance for device
3 Nov 2025Curaleaf QMID exclusive agreement; national launch NovemberNew recurring revenue stream
Nov 2025First MDMA capsule orders fulfilled in AustraliaPsychedelic commercialisation milestone
8 Dec 2025£500k SOSE loan drawnFunds Scotland build
11 Dec 2025Remidose agreement: Costa Rica and PanamaLATAM entry
24 Dec 2025Performance rights granted to KMP (share price, financial and KPI hurdles)Incentive alignment; dilution
Jan 2026Q2 FY2026 quarterly report; revised Appendix 4C lodgedRecord quarter (~A$17.3m); revision flagged as governance monitorable
29 Jan 2026Pitcher Partners replaces RSM as auditorAuditor transition
Feb 2026Scotland facility construction startsUK capacity build
26 Feb 2026H1 FY2026 results; adjusted EBITDA guidance upgraded ~40% to A$16.5–19.0mMajor positive revision; share price +13% on day
25 Mar 2026NWR Virtual Healthcare Conference presentationInvestor outreach
1 Apr 2026Aurora Cannabis manufacturing agreementBlue-chip validation
21 Apr 2026Q3 FY2026 report: record quarter; cash A$8.5m; FY2026 guidance reaffirmedOn track
11 May 2026Expanded Costa Rica supply agreement (first supply)LATAM progress
12 May 2026~A$50m two-year exclusive ADREXpharma agreementLargest contract to date; shares +19–24% on day
21 May 2026Notice of General Meeting (name change, consolidation)Corporate restructuring
3 Jun 2026Edward Myer appointed NEDGovernance strengthening
19 Jun 2026General Meeting approves name change—
29 Jun 20261:10 consolidation; name change to BLS Pharmaceuticals registeredCapital structure reset (229.98m shares)
7 Jul 2026Trading commences as ASX:BLSRebrand complete
21 Jul 2026Cayman Chemical international referral agreementPsychedelic platform expansion
27 Jul 2026Q4 FY2026 report: record quarterly revenue A$22.5m (unaudited); OCF A$6.3m; cash A$13.3mCash conversion turning point
30 Jul 2026Investor webinar presentation—
31 Aug 2026Audited FY2026 results; FY2027 guidance A$105–115m revenue, 23–26% EBITDA margin; Annual Report releasedShares +15% on day
Post 30 Jun 2026A$3m Westpac overdraft facility establishedLiquidity headroom
2 Sep 2026FY2026 results webinar—
Sep 2026Scheduled commissioning of Scottish facilityCompletion not confirmed in sources reviewed; guidance release cites completion by end of 2026
Late Oct 2026 (expected)Q1 FY2027 quarterly activities report / Appendix 4CNext scheduled disclosure (ASX quarterly deadline)

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2024–FY2026): Total revenue from customers rose from AUD 9.7 Mn in FY2024 to AUD 74.2 Mn in FY2026.
BLS Pharmaceuticals Limited — Revenue by Segment (FY2024–FY2026)
Series (AUD Mn)FY2024FY2025FY2026
Total revenue from customers9.728.474.2
PCC probiotic wholesale revenue——0.6
Pharmaceutical manufacturing and distribution——73.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.